Multiplex Assay Kit for Receptor Activator Of Nuclear Factor Kappa B Ligand (RANkL) ,etc. by FLIA (Flow Luminescence Immunoassay) Canis familiaris; Canine (Dog) Multiplex ELISA

CD254; TNFSF11; ODF; OPGL; TRANCE; HRANKL2; SOdf; Tumor Necrosis Factor(ligand)superfamily Member 11; TNF-related activation-induced cytokine

(Note: Up to 8-plex in one testing reaction)

Add to Cart Distributors
Overview
Properties
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Multiplex Assay Kit for Receptor Activator Of Nuclear Factor Kappa B Ligand (RANkL) ,etc. by FLIA (Flow Luminescence Immunoassay) Packages (Simulation)
  • Multiplex Assay Kit for Receptor Activator Of Nuclear Factor Kappa B Ligand (RANkL) ,etc. by FLIA (Flow Luminescence Immunoassay) Packages (Simulation)
  • Multiplex Assay Kit for Receptor Activator Of Nuclear Factor Kappa B Ligand (RANkL) ,etc. by FLIA (Flow Luminescence Immunoassay) Results demonstration
  • LMA855Ca.jpg Typical Standard Curve
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Recovery

Matrices listed below were spiked with certain level of recombinant Receptor Activator Of Nuclear Factor Kappa B Ligand (RANkL) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Receptor Activator Of Nuclear Factor Kappa B Ligand (RANkL) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 84-97 90
EDTA plasma(n=5) 85-99 88
heparin plasma(n=5) 80-97 84
sodium citrate plasma(n=5) 78-97 91

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Receptor Activator Of Nuclear Factor Kappa B Ligand (RANkL) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Receptor Activator Of Nuclear Factor Kappa B Ligand (RANkL) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Receptor Activator Of Nuclear Factor Kappa B Ligand (RANkL) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 95-104% 78-105% 90-104% 85-99%
EDTA plasma(n=5) 97-105% 85-99% 81-102% 78-91%
heparin plasma(n=5) 93-104% 84-97% 90-104% 94-105%
sodium citrate plasma(n=5) 95-104% 78-102% 99-105% 93-101%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:RANkL) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

Multiplex Assay Kit for Receptor Activator Of Nuclear Factor Kappa B Ligand (RANkL) ,etc. by FLIA (Flow Luminescence Immunoassay)

Test principle

Analyte-specific antibodies are pre-coated onto color-coded microparticles. Microparticles, standards, and samples are pipetted into wells and the immobilized antibodies bind the analytes of interest. After washing away any unbound substances, a biotinylated antibody cocktail specific to the analytes of interest is added to each well. Following a wash to remove any unbound biotinylated antibody, Streptavidin-Phycoerythrin conjugate (Streptavidin-PE), which binds to the biotinylated detection antibodies, is added to each well. A final wash removes unbound Streptavidin-PE and the microparticles are resuspended in buffer and read using the Luminex or Bio-Plex analyzer.The MFI developed is proportional to the concentration of analytes of interest in the sample.

Giveaways

Citations

  • Compressive stress induced the up-regulation of M-CSF, RANKL, TNF-α expression and the down-regulation of OPG expression in PDL cells via the integrin-FAK pathwayScienceDirect: S0003996912003998
  • Adipokines in Psoriatic Arthritis Patients: The Correlations with Osteoclast Precursors and Bone ErosionsPubMed: PMC3483160
  • Regulatory effect of calcineurin inhibitor, tacrolimus, on IL-6/sIL-6R-mediated RANKL expression through JAK2-STAT3-SOCS3 signaling pathway in fibroblast-like synoviocytesPubMed: PMC3672788
  • The effects of chronic zoledronate usage on the jaw and long bones evaluated using RANKL and osteoprotegerin levels in an animal modelPubmed: 23522850
  • Estrogen deficiency does not decrease the in vitro osteogenic potential of rat adipose-derived mesenchymal stem cellsPubmed: 24687841
  • Effects and mechanisms of 8-prenylnaringenin on osteoblast MC3T3-E1 and osteoclast-like cells RAW264.7Onlinelibrary: fsn3.109
  • Effects and mechanisms of 8‐prenylnaringenin on osteoblast MC3T3‐E1 and osteoclast‐like cells RAW264. 7Pubmed:Pmc4221832
  • Effect of Nicotine on RANKL and OPG and Bone Mineral DensityPubmed:24830656
  • Effects of icariin on the regulation of the OPG?RANKL?RANK system are mediated through the MAPK pathways in IL?1β?stimulated human SW1353 chondrosarcoma …Pubmed:25270538
  • Carvedilol promotes neurological function, reduces bone loss and attenuates cell damage after acute spinal cord injury in ratsPubmed:25424914
  • A novel model of bisphosphonate-related osteonecrosis of the jaw in ratsPubMed: 26191212
  • MicroRNA-106b inhibits osteoclastogenesis and osteolysis by targeting RANKL in giant cell tumor of bonePubMed: 26053181
  • Serum osteopontin levels are upregulated and predict disability after an ischaemic strokePubMed: 25845543
  • Effetti del laser a bassa dose su cellule osteoblasticheINCERTIPARENTI_SERENA_TESI.pdf
  • Noni leaf and black tea enhance bone regeneration in estrogen-deficient rats.pubmed:27908549
  • Extracorporeal shock waves alone or combined with raloxifene promote bone formation and suppress resorption in ovariectomized rats.pubmed:28158228
  • The effect of lamotrigine and phenytoin on bone turnover and bone strength: A prospective study in Wistar ratspubmed:27838501
  • Odontoclastogenesis of mouse papilla-derived MDPC-23 cells induced by lipopolysaccharide.pubmed:28333374
  • Sprint Interval Training Induces A Sexual Dimorphism but does not Improve Peak Bone Mass in Young and Healthy Mice.pubmed:28303909
  • Skeletal Site-specific Effects of Zoledronate on in vivo Bone Remodeling and in vitro BMSCs Osteogenic Activity.pubmed:28139685
  • Anti-osteoporotic effects of an antidepressant tianeptine on ovariectomized ratsS0753332216322752
  • SAT0003 The Role of 12/15-Lipoxygenase in The Pathogenesis of Osteoporosis in Micecontent:75
  • Allogeneic yet major histocompatibility complex‑matched bone marrow transplantation in mice results in an impairment of osteoblasts and a significantly reduced trabecular bonearticle:10.1007
  • Assessment of bone metabolism and biomechanical properties of the femur, following treatment with anastrozole and letrozole in an experimental model of menopauseol.2017.6596
  • Peroxisome proliferator‐activated receptor γ plays dual roles on experimental periodontitis in ratsPubmed:29574908
  • Effect of long-term administration of mangiferin from on bone metabolism in ovariectomized rats10.1016:j.jff.2018.04.048
  • Switched memory B cells promote alveolar bone damage during periodontitis: An adoptive transfer experimentPubmed:30015235
  • The effect of levetiracetam on rat bone mineral density, bone structure and biochemical markers of bone metabolismPubmed:29428468
  • Allogeneic yet major histocompatibility complex-matched bone marrow transplantation in mice results in an impairment of osteoblasts and a significantly reduced …Pubmed:28766138
  • Liraglutide exerts a bone‑protective effect in ovariectomized rats with streptozotocin‑induced diabetes by inhibiting osteoclastogenesisPubmed:29805533
  • The sole and combined effect of simvastatin and platelet rich fibrin as a filling material in induced bone defect in tibia of albino ratsPubmed: 30208342
  • Improved RANKL expression and osteoclastogenesis induction of CD27+ CD38− memory B cells: A link between B cells and alveolar bone damage in periodontitisPubmed: 30346027
  • NUMB maintains bone mass by promoting degradation of PTEN and GLI1 via ubiquitination in osteoblastsPubmed: 30455992
  • Alendronate Effect in RANKL Concentration at Ovariectomized Sprague Dawley Rat.
  • Development and characterization of supramolecular calcitonin assembly and assessment of its interactions with the bone remodelling processPubmed: 30797058
  • Evaluation of therapeutic effects of teriparatide in a rat model of zoledronic acid-induced bisphosphonate-related osteonecrosis
  • Comparison of RANKL expression, inflammatory markers, and cardiovascular risk in patients with acute coronary syndrome with and without rheumatoid arthritisPubmed: 31297563
  • Regulation of JAK/STAT signal pathway by miR-21 in the pathogenesis of juvenile idiopathic arthritisPubmed: 31641939
  • Mice lacking plastin-3 display a specific defect of cortical bone acquisitionPubmed: 31678489
  • IL-38 restrains inflammatory response of collagen-induced arthritis in rats via SIRT1/HIF-1α signaling pathwayPubmed: 32347300
  • Anti-osteoporosis effect of Semen Cuscutae in ovariectomized mice through inhibition of bone resorption by osteoclasts34801609
  • Inducible T‐cell co‐stimulator (ICOS) and ICOS ligand are novel players in the multiple‐myeloma microenvironmentPubmed:34954822
  • Jiangu granule ameliorated OVX rats bone loss by modulating gut microbiota-SCFAs-Treg/Th17 axisPubmed:35453007
  • Transcriptomic profiling revealed the role of apigenin-4′-O-α-L-rhamnoside in inhibiting the activation of rheumatoid arthritis fibroblast-like synoviocytes via MAPK …Pubmed:35660352
  • Identification of marker proteins in preterm and term birth: Relationship of rankl and HSP70 in the cord blood

Recommend products